Induction of apoptosis by esculetin in human leukemia U937 cells: Roles of Bcl-2 and extracellular-regulated kinase signaling
- Author(s)
- Cheol Park; Cheng-Yun Jin; Hyun Ju Kwon; Hye Jin Hwang; Gi-Young Kim; Il Whan Choi; Taeg Kyu Kwon; Byung-Woo Kim; Wun-Jae Kim; Yung Hyun Choi
- Keimyung Author(s)
- Kwon, Taeg Kyu
- Department
- Dept. of Immunology (면역학)
- Journal Title
- Toxicol In Vitro
- Issued Date
- 2010
- Volume
- 24
- Issue
- 2
- Keyword
- Esculetinl; Apoptosis; Bcl-2; HA14-1; ERK
- Abstract
- In the present study, we reported that apoptosis induced by esculetin, a phenolic compound with apop-
totic activity in cancer cells, was markedly blocked by Bcl-2-overexpression, but restored by HA14-1, a
small-molecule Bcl-2 inhibitor, in human leukemic U937 cells. The combined use of esculetin and
HA14-1 effectively induced Bid cleavage and loss of mitochondrial membrane potential (MMP, Dwm)
leading to the activation of caspases and cleavage of poly(ADP-ribose) polymerase (PARP) in Bcl-2-over-
expressing (U937/Bcl-2) cells. Combined treatment with esculetin and HA14-1 upregulated the expres-
sion of death receptor 4 (DR4), and activation of extracellular-regulated kinase (ERK) in a time-
dependent manner. In addition, esculetin and HA14-1-mediated apoptosis was reduced by ERK inhibitors
through inhibition of DR4 expression, suggesting that the synergistic effect was at least partially medi-
ated through ERK-dependent induction of DR4 expression. The results indicate that HA14-1-induced
reversal of the anti-apoptotic effect of Bcl-2 confers apoptosis sensitivity to esculetin by a mitochondrial
amplification step and through the ERK-dependent induction of DR4 expression in U937/Bcl-2 cells. Thus,
HA14-1 reversal of Bcl-2-mediated esculetin resistance suggests a novel strategy for increasing esculetin
sensitivity in Bcl-2-overexpressing leukemia cells.
2009 Elsevier Ltd. All rights reserved. Keywords:
Esculetinl
Apoptosis
Bcl-2
HA14-1
ERK
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.